<DOC>
	<DOCNO>NCT00183261</DOCNO>
	<brief_summary>The purpose study determine whether HIV vaccine MRKAd5 HIV-1 gag/pol/nef follow treatment interruption increase immune system function adult acute recent HIV infection start take anti-HIV drug .</brief_summary>
	<brief_title>Immune Response Therapeutic HIV Vaccine Followed Treatment Interruption Patients With Acute Recent HIV Infection</brief_title>
	<detailed_description>While advent highly active antiretroviral therapy ( HAART ) contribute increase control HIV infection viral replication , ultimate control HIV infection require development effective HIV-specific immunity HIV infected individual . Therapeutic vaccination within early week follow acute recent HIV infection may increase immune system 's response HIV . This study determine whether MRKAd5 HIV-1 gag/pol/nef vaccine follow treatment interruption maintain viral suppression patient acute recent HIV infection . The interventional part study last 102 week . Participants randomly assign receive either MRKAd5 HIV-1 gag/pol/nef placebo vaccine baseline Weeks 4 26 . Participants must remain HAART study entry Week 38 . Participants whose HIV viral load rebound two time 500 copies/ml Weeks 39 41 enter Step 2 study . Participants whose viral load drop 500 copies/ml less Weeks 39 41 enter Step 2 , discontinue HAART 24 week . Participants Step 2 plasma HIV viral load measure every 2 week first 4 week weekly next 3 week . Study participant continue Step 2 experience virologic immunologic failure need restart HAART another reason ; enter Step 3 , reinitiate HAART . Step 3 participant continue HAART Week 102 . A long-term safety follow-up period occur Weeks 103 240 . Timing study visit determine step participant enters . A physical exam blood urine collection occur study visit throughout study Week 102 . Follow-up phone call study participant occur every 6 month Week 102 Week 240 collect long-term safety data , include clinical status , CD4 count , medication history . During long-term safety follow-up , participant also study visit every 6 month . Visits include medical medication history .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Initiated HAART within 30 day acute recent HIV1 infection diagnosis . More information criterion find protocol . Initiated HAART within 30 day document acute recent HIV1 infection without interruption 7 day Sustained viral suppression , define viral load 500 copies/mL less 12 month prior baseline undetectable HIV1 RNA viral load 60 7 day prior baseline CD4 count 450 cells/mm3 OR 35 % 60 14 day prior baseline Ad5 neutralize antibody titer 200 less screen Willing follow study procedure schedule Willing interrupt HAART least 24 week follow completion vaccination stage Negative hepatitis B surface antigen ( HBsAg ) screen Willing use acceptable form contraception Infected HIV1 subtype B , information available Virologic relapse , define 2 consecutive measurement viral load 500 copies/mL least 7 day apart within 12 month baseline visit Received 7 day continuous HAART receive within 16 day acute recent HIV1 infection . Participants receive HAART part postexposure prophylaxis ( PEP ) 6 month prior start initial HAART may eligible , provide acquire HIV1 infection event require PEP . History anaphylaxis allergy vaccine component , include Tris buffer , magnesium chloride , polysorbate 80 ( Tween ) History clinically significant heart , lung , kidney , liver , pancreatic , gastrointestinal , neurological disease , opinion study investigator , may interfere study Contraindication intramuscular ( IM ) injection , anticoagulant therapy thrombocytopenia Receipt immune globulin blood product within 3 month prior baseline Receipt live vaccine within 30 day prior baseline inactivated vaccine within 14 day prior baseline Previous receipt HIV vaccine . Participants document received placebo exclude . History AIDSdefining illness . If participant 's sole AIDSdefining illness Kaposi 's sarcoma limit skin anticipate require systemic chemotherapy , participant exclude . Currently receive drug biologics approve Food Drug Administration ( FDA ) investigational HIV medication Current past participation study might alter participant 's response study vaccination Use immunomodulatory agent , include limited interleukin2 ( IL2 ) , granulocyte/macrophagecolony stimulate factor ( GMCSF ) , systemic corticosteroid , within 30 day prior baseline Active alcohol substance use , investigator 's opinion , may interfere study Any criterion condition , investigator 's opinion , may interfere study Unwilling unable contribute plan peripheral blood mononuclear cell ( PBMC ) blood collection Pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Treatment Interruption</keyword>
	<keyword>HIV Therapeutic Vaccine</keyword>
	<keyword>Acute Infection</keyword>
	<keyword>Acute Retroviral Syndrome</keyword>
</DOC>